Introduction {#s1}
============

Prion diseases, or transmissible spongiform encephalopathies, comprise a group of fatal neurodegenerative disorders in humans and animals for which there are no effective treatments or cures. These diseases are caused by refolding of the cellular prion protein (PrP^C^) into an infectious isoform (PrP^Sc^) that catalytically templates its abnormal conformation onto additional molecules of PrP^C^ ([@bib32]). A similar, prion-like process may play a role in other neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases and tauopathies, which are due to protein misfolding and aggregation ([@bib18]).

There is evidence that PrP^C^, in addition to serving as a precursor to PrP^Sc^, acts as a signal transducer that mediates the neurotoxic effects of PrP^Sc^ ([@bib3]; [@bib5]; [@bib8]; [@bib24]). Clues to possible mechanisms by which PrP^C^ can initiate neurotoxic activity have emerged from studies of transgenic mice expressing PrP molecules that harbor certain internal deletions within the N-terminal domain. The PrP^C^ molecule consists of a partially unstructured N-terminal domain (residues 23--125), and a globular, C-terminal domain (residues 126--230) comprising three α-helices and two short, β-strands ([@bib59]). Deletions spanning a 21-amino acid region (amino acids 105--125) at the end of the flexible, N-terminal domain induce a spontaneous neurodegenerative phenotype with certain similarities to natural prion diseases, but without accumulation of PrP^Sc^ ([@bib2]; [@bib23]; [@bib37]). Importantly, these phenotypes are dose-dependently suppressed by co-expression of wild-type PrP, suggesting that the wild-type and deleted molecules interact with each other, or compete for binding to a common molecular target that mediates both physiological and pathological effects. The shortest deletion, Δ105--125 (designated ΔCR, for [c]{.ul}entral [r]{.ul}egion), produces the most severe neurodegenerative phenotype, and requires the largest amount of wild-type PrP for rescue ([@bib23]).

In our efforts to understand why these deleted forms of PrP are so neurotoxic, we have discovered that they induce large, spontaneous ionic currents, recordable by patch clamping techniques, when expressed in a variety of cell lines ([@bib42], [@bib43]) and in primary neurons ([@bib4]). Remarkably, these currents are silenced by co-expression of wild-type PrP in the same cells, paralleling the rescuing effects of wild-type PrP in transgenic mice expressing deleted PrP. This observation suggests that the spontaneous ionic currents themselves, or some closely associated phenomenon, play a role in the neurodegenerative phenotype of these mice.

In this study, we uncover novel mechanistic features of the toxicity-inducing activities of PrP^C^. We show that ligands binding N-terminal domain of PrP^C^ abolish ΔCR PrP-induced currents, as do mutations of positively charged residues at the extreme N-terminus of this domain. Remarkably, expression of the isolated N-terminal domain in the absence of the C-terminal domain also induces spontaneous currents, indicating that the N-terminal domain is capable of acting as an autonomous, toxicity-determining effector. We also demonstrate that anti-PrP antibodies targeting epitopes in the structured, C-terminal domain induce ionic currents in cultured cells expressing wild-type PrP^C^, and cause degeneration of dendrites on hippocampal neurons. These results, taken together with structural evidence from heteronuclear NMR experiments, suggest a molecular model for PrP^C^ in which the N-terminal domain acts as a neurotoxic effector whose activity is regulated by the C-terminal domain. We speculate that this inter-domain regulatory interaction could play a role in the physiological function of PrP^C^, and that disruption of this interaction could contribute to pathology in neurodegenerative disorders. Our results also have important implications for the safety of anti-PrP antibody therapies for prion and Alzheimer's diseases.

Results {#s2}
=======

N-terminal ligands, and reversal of positive charges, block ΔCR-induced currents {#s2-1}
--------------------------------------------------------------------------------

Our previous studies identified a positively charged, nine amino acid segment at the very beginning of the N-terminal domain (residues 23--31, KKRPKPGGW) that is essential for the current activity of ΔCR PrP, and for the neurodegenerative phenotype of mice expressing another deletion mutant, Δ32--134 ([@bib43]; [@bib56]). As demonstrated in these earlier studies, deletion of residues 23--31 abolishes the spontaneous inward currents induced by ΔCR PrP ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), as does addition of pentosan polysulfate (PPS), a negatively-charged glycosaminoglycan which binds to several regions within the N-terminal domain ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). To probe further the role of the N-terminal domain in ΔCR PrP-induced currents, we tested the effect of additional ligands (antibodies and Cu^2+^ ions), as well alteration of positively charged residues within 23--31 region.

We tested two different anti-prion antibodies: 100B3 ([@bib48]), targeting residues 24--28, and POM11 ([@bib31]), which binds to the octapeptide repeats (residues 51--90). These antibodies (at concentrations of 57 nM and 33 nM, respectively), dramatically reduced ΔCR PrP-induced currents ([Figure 1A,B](#fig1){ref-type="fig"}). As a control for POM11, we tested the effect of this antibody on ΔCR/Δ51--90 PrP, which retains current activity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) as shown previously ([@bib43]), but which lacks the octapeptide repeat region and would not be expected to bind the antibody. As predicted, POM11 had relatively little effect on the currents induced by ΔCR/Δ51--90 PrP ([Figure 1B](#fig1){ref-type="fig"}), while 100B3 and PPS were still inhibitory ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). These results demonstrate that antibody ligands targeting the extreme N-terminus or the octapeptide repeats inhibit ΔCR PrP-induced currents. Interestingly, even though the octapeptide repeats are not required for current activity, binding of an antibody ligand to this region blocks the currents.10.7554/eLife.23473.003Figure 1.Ligands binding to the N-terminal domain of PrP^C^ block ΔCR-induced currents.(**A**) Left, representative traces of currents recorded from N2a cells expressing ΔCR or ΔCR/Δ51--90 PrP in the absence (upper traces) or presence (lower traces) of 100B3 (57 nM). Right, quantitation of the currents, plotted as the percentage of the total time the cells exhibited inward current ≥200 pA (mean ± S.E.M., n = 10). (**B**) Left, representative traces of currents recorded from N2a cells expressing ΔCR or ΔCR/Δ51--90 PrP in the absence (upper traces) or presence (lower traces) of POM11 (33.3 nM). Right, quantitation of the currents (mean ± S.E.M., n = 10). (**C**) Left, representative traces of currents recorded from N2a cells expressing ΔCR or ΔCR/Δ51--90 PrP in the absence (upper traces) or presence (lower traces) of Cu-pentaglycine (100 μM). Right, quantitation of the currents (mean ± S.E.M., n = 10). Scale bars in all panels: 1 nA, 30 s. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.003](10.7554/eLife.23473.003)10.7554/eLife.23473.004Figure 1---source data 1.Quantification of ΔCR PrP-induced currents w/o treatment of ligands binding to PrP^C^ N-terminus.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.004](10.7554/eLife.23473.004)10.7554/eLife.23473.005Figure 1---figure supplement 1.Mutated forms of PrP induce spontaneous currents.(**A**) Left, whole cell recordings were made from N2a cells transfected with empty vector, or vector encoding WT, ΔCR, ΔCR/Δ51--90, ΔCR/Δ23--31, or ΔCR/E3D PrP. Right, quantitation of the currents, plotted as the percentage of the total time the cells exhibited inward current ≥200 pA (mean ± S.E.M., n = 10). (**B**) Left, representative traces of currents recorded from N2a cells expressing ΔCR or ΔCR/Δ51--90 PrP in the absence (upper traces) or presence (lower traces) of PPS (100 μg/ml). Right, quantitation of the currents (mean ± S.E.M., n = 10). \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.005](10.7554/eLife.23473.005)10.7554/eLife.23473.006Figure 1---figure supplement 2.Surface immunofluorescence staining of PrP^C^ on N2a cells expressing ΔCR after treatment with N-terminal ligands.Living N2a cells co-transfected with a ΔCR PrP-encoding plasmid along with an EGFP marker plasmid were treated with the indicated ligands, and then stained with anti-PrP antibody D18, followed by fixation and incubation with red fluorescent secondary antibody. Representative fluorescence images show surface expression of PrP (red), EGFP fluorescence (green), and DAPI nuclear staining (blue). Scale bar: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.006](10.7554/eLife.23473.006)

To further investigate the role of the octapeptide repeats, we tested the effect of Cu^2+^ ions, which are known to bind to histidine residues located within four of the five octapeptide repeats and at positions 95 and 110 ([@bib27]). We found that treatment with Cu^2+^-pentaglycine (100 μM) blocked spontaneous currents in N2a cells expressing ΔCR PrP, but not in cells expressing ΔCR/Δ51--90 ([Figure 1C](#fig1){ref-type="fig"}). Pentaglycine, with a K~d~ for Cu^2+^ similar to that of PrP^C^ (40 nM), was included as a Cu^2+^ chelator in order to minimize the concentration of free Cu^2+^ (1 μM) while still allowing PrP^C^ to compete for Cu^2+^ ions. This result indicates that Cu^2+^ coordination to the octapeptide repeats blocks ΔCR PrP currents.

Both PPS and copper have been shown to induce endocytosis of PrP^C^ from cell surface ([@bib6]; [@bib30]; [@bib38]). To determine whether ligand binding to the N-terminus blocked ΔCR PrP-induced currents by reducing the amount of the mutant protein on the cell surface, living cells were treated with PPS for 1 hr or Cu^2+^-pentaglycine for 5 min in recording buffer at room temperature, and then surface-stained for ΔCR PrP with anti-PrP antibody. Under these conditions, neither ligand altered the amount of ΔCR PrP on the cell surface ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), presumably because of the short period of treatment and the fact that the experiment was conducted at room temperature rather than 37°C. As reported previously ([@bib6]; [@bib30]; [@bib38]), PPS did induce significant endocytosis after treatment at 37°C for 48 hr ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Cells treated with 100B3 or POM11 for 48 hr at 37°C did not show any change in surface level of ΔCR PrP ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Thus, the inhibitory effects of PPS, POM11, 100B3 and Cu^2+^ did not result from acute changes in localization or trafficking of the mutant protein.

The extreme N-terminus of PrP^C^ contains four positively charged amino acids (~23~**KKR**P**K**PGGW~31~). To test the role of these residues in ΔCR-induced currents, we generated a variant of ΔCR (designated ΔCR/E3D) in which the three lysine residues (at positions 23, 24, and 27) were mutated to glutamic acid and the single arginine residue (at position 25) was mutated to aspartic acid. We found that N2a cells expressing this mutant did not show any currents ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This result indicates that the positive charges within the 23--31 segment are essential for ΔCR-induced spontaneous currents.

The N-terminal domain of PrP^C^ induces ionic currents in the absence of the C-terminal domain {#s2-2}
----------------------------------------------------------------------------------------------

Having shown that the N-terminal domain of PrP^C^ is essential for ΔCR PrP-induced currents, we wished to determine whether N-terminus is, by itself, sufficient to induce spontaneous currents. We constructed a series of chimeric proteins (collectively designated PrP(N)-EGFP-GPI) consisting of various lengths of the N-terminal domain of PrP^C^ (residues 23--109) fused to an EGFP molecule that was equipped with the GPI addition signal from PrP^C^ ([Figure 2A](#fig2){ref-type="fig"}). It was necessary to include the EGFP moiety to enable efficient delivery of the protein to the cell surface ([@bib17]); fusing the N-terminal domain directly to the GPI addition signal results in a protein that is largely retained in the ER and is degraded by the proteasome ([@bib10]). We confirmed cell surface localization of the PrP(N)-EGFP-GPI constructs in transfected cells by fluorescence microscopy ([Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.23473.007Figure 2.The N-terminal domain of PrP^C^ induces ionic currents in the absence of the C-terminal domain.(**A**) Schematic of PrP(N)-EGFP-GPI constructs containing the N-terminus of PrP fused to EGFP and the PrP GPI attachment sequence. The colored blocks represent the signal sequence (blue), polybasic residues 23--31 (yellow), different portions of the N-terminus (grey), EGFP (green), and the GPI attachment sequence (magenta). (**B**) Fluorescence image of N2a cells expressing PrP(1-109)-EGFP-GPI, showing localization of the protein on the cell surface. Scale bar = 10 μm. (**C**) Left, representative traces of currents recorded from N2a cells expressing constructs with different lengths of the N-terminus (1--31, 1--58, 1--90, 1--109 and 32--109). Scale bars: 500 pA, 30 s. Right, quantitation of the currents, plotted as the percentage of the total time the cells exhibited inward current ≥200 pA (mean ± S.E.M., n = 5 cells). \*p\<0.05; \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.007](10.7554/eLife.23473.007)10.7554/eLife.23473.008Figure 2---source data 1.Quantification of N1-GFP-GPI-induced currents N2a cells.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.008](10.7554/eLife.23473.008)10.7554/eLife.23473.009Figure 2---figure supplement 1.Currents induced by PrP(1-109)-EGFP-GPI have the same features as currents induced by ΔCR PrP.(**A**) Representative traces of currents recorded from N2a cells expressing PrP(1-109)-EGFP-GPI or Δ23--89 PrP. (**B**) Left, representative traces of currents recorded from N2a cells expressing PrP(1-109)-EGFP-GPI in the absence of treatment, or in the presence of PPS (100 μg/ml), POM11 (16.7 nM) or Cu-pentaglycine (100 μM). Right, quantitation of the currents, plotted as the percentage of the total time the cells exhibited inward current ≥200 pA. (mean ± S.E.M., n = 10). (**C**) Left, representative traces of currents recorded from N2a cells transfected with a plasmid encoding ΔCR PrP, or co-transfected with plasmids encoding ΔCR PrP and WT PrP at the indicated ratios. Right, quantitation of the currents (mean ± S.E.M., n = 10). (**D**) Left, representative traces of currents recorded from N2a cells transfected with a plasmid encoding PrP(1-109)-EGFP-GPI, or co-transfected with plasmids encoding PrP(1-109)-EGFP-GPI and WT PrP at the indicated ratios. Right, quantitation of the currents (mean ± S.E.M., n = 10). (**E**) Quantitation of the currents recorded from N2a cells transfected with a plasmid encoding ΔCR PrP, or co-transfected with plasmids encoding ΔCR PrP and Δ23--31 PrP at the indicated ratios. (mean ± S.E.M., n = 10). (**F**) Quantitation of the currents recorded from N2a cells transfected with a plasmid encoding PrP(1-109)-EGFP-GPI, or co-transfected with plasmids encoding PrP(1-109)-EGFP-GPI and Δ23--31 PrP at the indicated ratios. (mean ± S.E.M., n = 10). (**G**) Left, representative traces of currents recorded from N2a cells expressing ΔCR PrP at holding potentials of −30 mV, −50 mV and −70 mV. Right, quantitation of the current at each holding potential (mean ± S.E.M., n = 10). (**H**) Left, representative traces of currents recorded from N2a cells expressing PrP(1-109)-EGFP-GPI at holding potentials of −30 mV, −50 mV and −70 mV. Right, quantitation of the current at each holding potential (mean ± S.E.M., n = 10). Except for panels G and H, the holding potential for all experiments was −70 mV. Scale bar in all panels: 1 nA, 30 s. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.009](10.7554/eLife.23473.009)

We found that cells expressing PrP(N)-EGFP-GPI constructs displayed spontaneous ionic currents. The most active currents were observed with a construct encompassing PrP residues 1--109, with successively lower current activities seen as the constructs became shorter ([Figure 2C,D](#fig2){ref-type="fig"}). Importantly, the PrP 32--109 construct was much less active, demonstrating the dependence of current activity on the 23--31 region ([Figure 2C,D](#fig2){ref-type="fig"}). Expression of the C-terminal domain of PrP^C^ (Δ23--89 PrP) did not induce any currents ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}).

We note that ΔCR/Δ51--90 PrP ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) was more effective at inducing currents than 1--31-EGFP or 1--59-EGFP ([Figure 2](#fig2){ref-type="fig"}). There are at least two possible reasons for this observation. First, the ΔCR/Δ51--90 PrP construct contains additional sequences that are not present in the 1--31-EGFP or 1--59-EGFP constructs. In particular, ΔCR/Δ51--90 PrP contains residues 91--104, which are absent in 1--31-EGFP and 1--59-EGFP. These additional residues may enhance production of spontaneous currents, consistent with the general observation that PrP-EGFP chimeras incorporating longer stretches of the PrP N-terminus produced more currents ([Figure 2C](#fig2){ref-type="fig"}). A second possible explanation is that the EGFP portion of the chimeric constructs may position the PrP N-terminus at a different distance from the membrane, or in a different orientation, than the natural PrP^C^ C-terminus, and this may diminish the ability of the N-terminus to interact with the membrane to produce currents.

The spontaneous currents associated with PrP(N)-EGFP-GPI had characteristics identical to the currents associated with ΔCR PrP. First, PrP(N)-EGFP-GPI currents were sporadic in nature, and were silenced by N-terminal ligands, including PPS, 100B3, POM11, and Cu^2+^-pentaglycine ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Second, PrP(N)-EGFP-GPI currents, like ΔCR PrP currents, were silenced in a dose-dependent fashion by co-expression of WT PrP ([Figure 2---figure supplement 1C and D](#fig2s1){ref-type="fig"}). Moreover, removal of 23--31 region abolished the ability of WT PrP^C^ to suppress both ΔCR and PrP(N)-EGFP-GPI currents ([Figure 2---figure supplement 1E and F](#fig2s1){ref-type="fig"}), which is consistent with the observation that expression of Δ23--31 PrP does not rescue the neurodegenerative phenotype of mice expressing Δ32--134 PrP ([@bib49]). Finally, the currents induced by both ΔCR and PrP(N)-EGFP-GPI were voltage-dependent, only being observed at holding potentials below −30 mV ([Figure 2---figure supplement 1G and H](#fig2s1){ref-type="fig"}).

NMR analysis reveals diminished interaction between the N- and C-terminal domains of ΔCR PrP {#s2-3}
--------------------------------------------------------------------------------------------

The results presented thus far suggest that the C-terminal domain of PrP^C^ may directly regulate the N-terminal domain through a cis-interaction between the two domains. This interaction may be disrupted by deletion of residues in the central region (as in ΔCR), or by substitution of an unrelated protein for the C-terminal domain (as in PrP(N)-EGFP-GPI). Recently, [@bib13] used ^1^H-^15^N HSQC NMR to demonstrate that Cu^2+^ ions, when bound to the N-terminal, octapeptide repeats, promote contact between these repeats and a C-terminal surface site encompassing helices 2 and 3. We predicted that this *cis* interaction would be weakened in ΔCR, thereby accounting for the ability of the liberated N-terminal domain to induce spontaneous currents.

To test this prediction, we employed paramagnetic relaxation enhancement to probe the interaction between octapeptide-bound Cu^2+^ ions and residues in the C-terminal domain. Using the methods of [@bib13], we compared the ^1^H-^15^N HSQC NMR spectra of recombinant, wild-type mouse PrP (WT PrP) and ΔCR PrP in the presence and absence of one equivalent of Cu^2+^ ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Residues that come in close proximity to Cu^2+^ have their NMR cross-peaks broadened, resulting in a lower observed intensity. For example, in the absence of Cu^2+^, a large cross-peak shown in black corresponding to WT PrP residue E199 was observed ([Figure 3---figure supplement 1--A1](#fig3s1){ref-type="fig"}). However, upon the addition of one equivalent of Cu^2+^ the corresponding cross-peak depicted in red for residue E199 was greatly diminished in intensity. On the other hand, when Cu^2+^ was titrated into ΔCR PrP, only a small shift between positions of the cross-peaks corresponding to E199 was observed ([Figure 3---figure supplement 1--A2](#fig3s1){ref-type="fig"}). The chemical shift changes, mapped onto the structure of WTPrP in [Figure 3A,B](#fig3){ref-type="fig"}, identify those residues in the C-terminal domain affected by Cu^2+^ binding to the octapeptide repeats. In [Figure 3A1 and A2](#fig3){ref-type="fig"}, residues that do not significantly change upon addition of Cu^2+^ are indicated by blue bars, while residues that underwent a significant reduction in intensity are indicated by red bars. Cross-peaks that were not identified are not shown in the figure. The large interaction patch seen in WT PrP is clearly reduced in the ΔCR mutant (compare the residues highlighted in magenta in [Figure 3B1/C1 and B2/C2](#fig3){ref-type="fig"}), especially in helices 2 and 3. These data suggest that deletion of residues in the central region disrupts a Cu^2+^-driven regulatory interaction between the N- and C-terminal domains.10.7554/eLife.23473.010Figure 3.ΔCR PrP shows diminished interaction between N- and C-terminal domains based on NMR analysis.(**A**) Reduction in peak intensities of ^1^H-^15^N HSQC spectra of WT PrP (A1) and ΔCR PrP (A2) in the presence of Cu^2+^. Data are shown only for the structured domain (residues 90--230). I/I~0~ values represent the ratios of peak heights in the presence and absence of 1 equivalent of Cu ^2+^. Residues with I/I~0~ values less than 1.0 SD below the mean (dotted line) are shown in red, with unassigned residues omitted. (**B**) Residues (labeled and colored magenta) of WT PrP (B1) and ΔCR PrP (B2) with I/I~0~values \< 1.0 SD below the mean, mapped onto a ribbon representation of the NMR structure of mouse PrP(120-230) (PDB:1XYX). (**C**) Affected residues (magenta) of WT PrP (C1) and ΔCR PrP (C2) are mapped onto surface plots of mouse PrP(120-230) (PDB:1XYX).**DOI:** [http://dx.doi.org/10.7554/eLife.23473.010](10.7554/eLife.23473.010)10.7554/eLife.23473.011Figure 3---figure supplement 1.NMR signals for C-terminal residues broaden in the presence of Cu^2+^ bound to the N-terminal octarepeats.Selected regions of the ^1^H-^15^N HSQC paramagnetic relaxation enhancement NMR spectra of WT PrP (A1) and ΔCR PrP (A2) in the absence of metal (black) and in the presence of 1 equivalent of Cu^2+^ (red). Spectra were acquired on a Varian INOVA 600-MHz spectrometer at pH 5.5, 300 μM protein, and 37°C.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.011](10.7554/eLife.23473.011)

Antibodies against the C-terminal domain and hinge region of PrP^C^ induce ionic currents {#s2-4}
-----------------------------------------------------------------------------------------

Previous studies have reported that antibodies targeting specific epitopes in the structured domain of PrP^C^ cause neuronal death when administered in vivo or in brain slices ([@bib33]; [@bib40]; [@bib44]). We wondered whether the neurotoxicity of anti-PrP antibodies might be due to their ability to induce ionic currents, similar to the way that ΔCR PrP causes ionic currents in cultured cells ([@bib42], [@bib43]) and neuronal death in transgenic mice ([@bib23]). We found that two antibodies targeting overlapping epitopes encompassing helix 1 in the C-terminal half of PrP^C^, POM1 ([@bib31]; [@bib44]) and D18 ([@bib12]; [@bib58]), induced spontaneous currents in N2a cells expressing WT PrP^C^ ([Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.23473.012Figure 4.Antibodies against the C-terminal domain induce ionic currents in N2a cells expressing wild-type PrP^C^.(**A**) Left, representative traces of spontaneous currents recorded from cells expressing ΔCR PrP (top traces), and currents induced by anti-prion antibodies (POM1 and D18) in cells expressing WT PrP (lower traces) in the absence (left-hand traces) or presence (right-hand traces) of PPS (100 ug/ml). Right, quantitative analysis of the currents, plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA. (mean ± S.E.M., n = 10). (**B**) Left, representative traces of currents recorded from cells expressing WT PrP in the presence of POM1, POM11, or POM1+POM11. Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). (**C**) Left, representative traces of currents recorded from cells expressing WT PrP in the presence of D18, POM11, or D18+POM11. Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). (**D**) Left, representative traces of currents induced by POM1 (upper traces) or D18 (lower traces) in cells expressing WT PrP (left-hand traces) or Δ23--31 PrP (center traces), or in cells expressing WT PrP after pretreatment with PIPLC (1.0 units/ml for 4 hr at 37°C) (right-hand traces). Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). Scale bars in all panels: 1 nA, 30 s. \*\*p\<0.01; \*\*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.012](10.7554/eLife.23473.012)10.7554/eLife.23473.013Figure 4---source data 1.Quantification of anti-prion antibody-induced currents on N2a cells.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.013](10.7554/eLife.23473.013)10.7554/eLife.23473.014Figure 4---figure supplement 1.ICSM-18 induces currents in N2a cells.(**A**) Left, representative traces of currents induced in N2a cells over-expressing WT PrP by non-specific IgG (33.3 nM) (upper trace), ICSM-18 (33.3 nM) (middle trace) or ICSM-18 (33.3 nM) in the presence of PPS (100 μg/ml) (lower trace). Right, quantitative analysis of the currents, plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA. (mean ± S.E.M., n = 5). \*\*p\<0.01. (**B**) Left, representative traces of currents induced in N2a cells over-expressing WT PrP by control scFv antibody (anti-fluorescein, 200 nM) (upper trace), ICSM-18 scFv (200 nM) (middle trace), or ICSM-18 scFv (200 nM) in the presence of PPS (100 μg/ml) (lower trace). Right, quantitative analysis of the currents, plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA. (mean ± S.E.M., n = 20). \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.014](10.7554/eLife.23473.014)10.7554/eLife.23473.015Figure 4---figure supplement 2.Antibody-induced currents are dependent on PrP^C^ expression level and are produced by Fab fragments.(**A**) Quantitation of currents produced by D18 or POM1 treatment of transfected N2a cells over-expressing WT PrP, untransfected N2a cells, or PrP-null N2a cells. Currents are plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA. (mean ± S.E.M., n = 10). \*p\<0.05, \*\*p\<0.01. (**B**) Left, representative traces of currents recorded from PrP-over-expressing N2a cells in the presence of D18 or an Fab fragment of D18. Right, quantitative analysis of the currents (mean ± S.E.M., n = 10).**DOI:** [http://dx.doi.org/10.7554/eLife.23473.015](10.7554/eLife.23473.015)10.7554/eLife.23473.016Figure 4---figure supplement 3.6D11, but not other central region antibodies, weakly induces currents in N2a cells.Left, representative traces of currents induced by antibodies 6D11, POM3, D13, and ICSM-35 at the indicated concentrations in N2a cells over-expressing WT PrP. Scale bar: 1 nA, 30 s. Right, quantitation of the currents, plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA. (mean ± S.E.M., n = 10).**DOI:** [http://dx.doi.org/10.7554/eLife.23473.016](10.7554/eLife.23473.016)10.7554/eLife.23473.017Figure 4---figure supplement 4.POM1, but not antibodies recognizing other regions of the C-terminal domain, induces currents.Left, representative traces of currents induced by antibodies POM1, POM4 and POM6 at the indicated concentrations in N2a cells over-expressing WT PrP. Scale bar: 1 nA, 30 s. Right, quantitation of the currents, plotted as the percentage of the recording time the cells exhibited inward currents ≥200 pA (mean ± S.E.M., n = 10).**DOI:** [http://dx.doi.org/10.7554/eLife.23473.017](10.7554/eLife.23473.017)10.7554/eLife.23473.018Figure 4---figure supplement 5.D18 induces currents in Tga20 hippocampal neurons over-expressing WT PrP and in wild-type neurons, but not in PrP knock-out (KO) neurons.Top, D18 induces currents in Tga20 hippocampal neurons in the absence (left) but not the presence (right) of PPS (100 μg/ml). Scale bar: 1 nA, 30 s. Bottom, D18 induces weak currents in wild-type hippocampal neurons (left), but not in PrP KO neurons (right). Scale bar: 1 nA, 30 s. Pie charts show the proportions of three categories of neurons: Light grey represents neurons from which recordings were made for \>5 min without any currents; dark grey represents neurons that exhibited spontaneous currents, and in which voltage-clamped could be maintained throughout the 5 min recording period; black represents neurons in which voltage-clamp was lost during the 5-min recording period.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.018](10.7554/eLife.23473.018)

A third anti-prion antibody with a similar epitope, ICSM-18 ([@bib1]), had a comparable effect, which was blocked by PPS and was absent with non-specific mouse IgG ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Because we were not able to obtain sufficient amounts of ICSM-18 for further electrophysiological experiments, we turned to a single chain version of this antibody (ICSM-18 scFv). Like the holo-antibody, ICSM-18 scFv-induced spontaneous currents on on N2a cells overexpressing WT PrP^C^ ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), although higher concentrations were required (200 nM for the scFv version, compared to 33.3 nM for the holo-antibody), presumably reflecting the lower avidity of the monovalent scFv antibodies ([@bib25]). The spontaneous currents induced by ICSM-18 scFv were abolished by PPS (100 μg/ml), and were absent with a control scFv ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

The properties of the D18-, POM1-, and ICSM-18-induced currents were identical to those of the spontaneous currents associated with ΔCR PrP, in terms of their sporadic nature, and suppression by PPS ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). In addition, treatment of WT PrP-expressing N2a cells with POM11 blocked POM1- or D18-induced currents ([Figure 4B and C](#fig4){ref-type="fig"}), similar to the inhibitory effect of POM11 on ΔCR PrP currents ([Figure 1](#fig1){ref-type="fig"}). Finally, cells expressing PrP with a deletion of residues 23--31 were resistant to current induction by POM1 and D18 antibodies ([Figure 4D](#fig4){ref-type="fig"}), parallel to the situation with ΔCR PrP, and emphasizing the importance of the polybasic region in antibody-induced current generation. One would expect a significant reduction in antibody-induced currents in N2a cells expressing Δ23--31 PrP compared to cells over-expressing WT PrP (as observed in [Figure 4D](#fig4){ref-type="fig"}), since the endogenous level of WT PrP in N2a cells is low, and we have shown that untransfected cells display reduced currents after antibody treatment ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). The fact that the Δ23--31-expressing cells do not display even low levels of current due to endogenous PrP^C^ may be due to some suppression of endogenous PrP expression, or perhaps competition by the deleted protein for binding of the antibodies.

We performed several control experiments to demonstrate that the antibody-induced currents were dependent on expression of cell-surface PrP^C^. First, we pretreated transfected N2a cells expressing WT PrP with phosphatidylinositol-specific phospholipase C (PIPLC) at 1 U/ml for 4 hr at 37°C, which cleaves the C-terminal GPI anchor and releases PrP^C^ from the cell membrane. Neither D18 nor POM1 induced currents in PIPLC pretreated cells ([Figure 4D](#fig4){ref-type="fig"}). Second, we demonstrated that D18 did not induce currents in N2a cells in which PrP gene expression had been abolished by CRISPR-Cas technology ([@bib26]) ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). Finally, we observed that D18 induced currents in untransfected N2a cells, although they were smaller than in transfected N2a cells over-expressing WT PrP^C^, presumably due to the lower expression level of PrP^C^ in the former cells ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). Taken together, these results indicate that D18 and POM1-induced currents are PrP-dependent and are due to binding of the antibodies to cell-surface PrP^C^.

To determine whether antibody-induced currents were the result of cross-linking of cell-surface PrP^C^, or Fc-mediated antibody effector functions, we tested the effect of monovalent Fab fragments. We found that Fab fragments prepared from D18-induced currents on N2a cells ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). This result, along with the effectiveness of ICSM-18 scFv antibody ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), indicates that the ability of the C-terminally directed antibodies to induce currents in PrP-expressing cells is not due to cross-linking of cell-surface PrP by bivalent binding, or to Fc-mediated effector functions such as complement fixation.

The antibody 6D11 ([@bib28]), whose epitope (residues 93--109) encompasses several positively charged residues following the octapeptide repeats, also induced currents in WT PrP-expressing N2a cells ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). However, this antibody was less potent than POM1 and D18, since the currents were much smaller, and higher concentrations were required to produce consistent effects (66.7 nM for 6D11, compared to 33.3 nM for POM1 and 16.7 nM for D18) ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}). 6D11 and three other antibodies targeting this region, D13 ([@bib58]) (epitope: a.a. 95--105), POM3 ([@bib31]) (epitope: a.a. 95--100) and ICSM-35 ([@bib19]) (epitope: a.a. 93--105), did not induce currents at a concentration of 33.3 nM ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Taken together, these results indicate that antibodies targeting a positively charged segment at the terminus of the flexible domain are less effective at inducing currents than antibodies binding to helix 1 in the C-terminal, structured domain.

To explore further the epitope specificity of the antibody-induced currents, we tested two additional POM antibodies recognizing other epitopes in the C-terminal domain of PrP^C^. We found that POM4 (whose epitope encompasses helix 3 and β1) and POM6 (which recognizes helices 1 and 2) did not produce detectable currents when applied to WT PrP-expressing N2a cells at a concentration of 33.3 nM ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}).

We tested whether anti-PrP antibodies induce currents in hippocampal neurons, as well as in N2a cells. Treatment with D18 (33.3 nM) induced large, spontaneous inward in hippocampal neurons cultured from Tga20 mice over-expressing wild-type PrP, and also increased the fragility of these neurons ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Eight of 10 Tga20 neurons analyzed in the presence of D18 were lost to observation shortly after breaking the patch, usually after recording an initial inward current that did not return to baseline. This phenomenon is similar to what we previously observed in cultured neurons expressing ΔCR PrP ([@bib4]), and may reflect a detrimental effect of the induced currents on the integrity of the neuronal membrane. In contrast, recordings from Tga20 neurons in the presence of D18 and PPS remained stable for 5 min without current activity ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Seven out of 15 wild-type neurons analyzed in the presence of D18 exhibited spontaneous currents, with no lost cells. D18 did not induce any currents in neurons from *Prnp^−/−^* mice, which lack PrP expression.

Antibodies recognizing the C-terminal domain of PrP^C^ induce dendritic degeneration in hippocampal neurons {#s2-5}
-----------------------------------------------------------------------------------------------------------

Given the correlation between ΔCR PrP-induced currents and neurotoxicity, we hypothesized that anti-PrP antibodies might have neurotoxic effects on cultured hippocampal neurons as a result of the currents induced by these antibodies. To test this idea, we treated hippocampal neurons cultured from Tga20 mice with D18 (16.7 nM) or POM1 (33.3 nM) for 48 hr, and then stained them with an antibody to MAP2 to visualize changes in dendritic morphology. We observed that treatment with D18 or POM1 caused dendrites to assume a characteristic 'beaded' appearance, which is typical of several kinds of toxic insults, including hypoxia and glutamate-induced excitotoxicity ([@bib15]) ([Figure 5A](#fig5){ref-type="fig"}). This effect was less in wild-type neurons and completely absent in *Prnp*^−/−^ hippocampal neurons, indicating a dependence on the expression level of PrP^C^ ([Figure 5A](#fig5){ref-type="fig"}). Treatment of neurons with non-specific mouse IgG had no effect on dendritic morphology ([Figure 5A](#fig5){ref-type="fig"}). Antibody 6D11, which weakly induced currents in WT PrP-over-expressing N2a cells at 66.7 nM ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}) induced mild dendrite degeneration in Tga20 neurons ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), while ICSM-35 at 33.3 nM, which did not induce currents, did not cause dendritic degeneration ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Similarly, POM4 (33.3 nM) and POM6 (33.3 nM) had no effect on dendritic morphology ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).10.7554/eLife.23473.019Figure 5.Antibodies recognizing the C-terminal domain of PrP^C^ induce dendritic degeneration in hippocampal neurons.(**A**) Top, representative images showing dendrite morphology of cultured hippocampal neurons from Tga20 mice (which over-express WT PrP^C^), WT mice, or *Prnp*^−/−^ mice after treatment for 48 hr with D18 (16.7 nM), POM1 (33.3 nM) or non-specific IgG (33.3 nM). The cells were stained with an antibody to MAP2 to visualize dendrites. Boxed areas are enlarged below each image. Scale bar = 10 µm. Bottom, quantitation of dendritic degeneration, expressed as the length of beaded dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each experimental condition. Data represent mean ± S.E.M. \*\*p\<0.01; \*\*\*p\<0.005. (**B--D**) Quantitation of dendritic beading following treatment with IgG, D18 alone, N-terminal ligand (PPS, 100B3, or POM11) alone, or D18 together with the N-terminal ligand. Data represent mean ± S.E.M. \*\*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.019](10.7554/eLife.23473.019)10.7554/eLife.23473.020Figure 5---source data 1.Quantification of dendritic degeneration, expressed as the length of beaded dendrite segments as a percentage of total dendrite length.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.020](10.7554/eLife.23473.020)10.7554/eLife.23473.021Figure 5---figure supplement 1.6D11, but not ICSM35, has a weak effect on the dendritic morphology of Tga20 hippocampal neurons.(**A**) Representative images showing dendrite morphology after treatment with 6D11 or non-specific IgG (66.7 nM each). (**B**) Representative images showing dendrite morphology after treatment with ICSM-35 or non-specific IgG (33.3 nM each). Neurons were stained for an antibody to MAP2 to visualize dendrites. Scale bar: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.021](10.7554/eLife.23473.021)10.7554/eLife.23473.022Figure 5---figure supplement 2.POM4 and POM6 have no effect on the dendritic morphology of Tga20 hippocampal neurons.Representative images showing dendrite morphology of cultured hippocampal neurons from Tga20 mice (upper panels), WT mice (middle panels), or *Prnp*^−/−^ mice (lower panels) after treatment for 48 hr with POM1 (33.3 nM) (left-hand panels), POM4 (33.3 nM) (center panels), or POM6 (33.3 nM) (right-hand panels). Scale bar: 10 μM.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.022](10.7554/eLife.23473.022)

We tested whether antibody-induced dendritic changes, like currents, were dependent on the N-terminal domain of PrP^C^. Supporting such a correlation, D18 had no effect on dendritic morphology of hippocampal neurons cultured from mice expressing Δ23--31 or Δ23--111 PrP ([Figure 6](#fig6){ref-type="fig"}), demonstrating that the N-terminal domain is essential for both the dendrotoxic and current-inducing effects of the antibody. In addition, we found that co-treatment of neurons with the N-terminal ligands PPS, 100B3, or POM11 abolished D18-induced dendritic degeneration ([Figure 5B--D](#fig5){ref-type="fig"}), analogous to the way these ligands inhibit D18-induced currents ([Figure 4A--C](#fig4){ref-type="fig"}).10.7554/eLife.23473.023Figure 6.D18 does not induce dendritic degeneration in hippocampal neurons cultured from Δ23--31 or Δ23--111 transgenic mice on the *Prnp*^−/−^ background.Representative images showing dendrite morphology of cultured hippocampal neurons from mice expressing Δ23--31 PrP (upper panels) or Δ23--111 PrP (lower panels) after treatment for 48 hr with D18 (16.7 nM) (left-hand panels) or non-specific IgG (16.7 nM) (right-hand panels). Neurons were stained for an antibody to MAP2 to visualize dendrites. Scale bar: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.023](10.7554/eLife.23473.023)

Given the proposed use of a humanized version of ICSM-18 as an immunotherapeutic for prion and Alzheimer's diseases in patients ([@bib20]), we tested whether ICSM-18 induces dendritic toxicity. We observed that treatment of neurons cultured from Tga20 mice with ICSM-18 (6.67 nM) for 48 hr caused significant beading of dendrites, similar to the effects of POM1 and D18 ([Figure 7A](#fig7){ref-type="fig"}). At higher concentrations (33.3 nM), ICSM-18 caused significant loss of neuronal cell bodies after 48 hr of treatment (not shown). In control experiments, no morphological effects were observed with non-specific IgG (6.67 nM), or after treatment of neurons from *Prnp*^−/−^ mice with ICSM-18 ([Figure 7A](#fig7){ref-type="fig"}). ICSM-18 scFv (200 nM) also induced dendritic degeneration on neurons cultured from Tga20 mice but not *Prnp*^−/−^ mice, although the effect was milder than for the ICSM-18 holo-antibody ([Figure 7B](#fig7){ref-type="fig"}).10.7554/eLife.23473.024Figure 7.Anti-prion antibody ICSM-18 induces dendritic degeneration in hippocampal neurons.(**A**) Left, representative images showing dendrite morphology of cultured hippocampal neurons from Tga20 mice (which over-express WT PrP^C^) (left-hand panels) or *Prnp*^−/−^ mice (right-hand panels) after treatment for 48 hr with non-specific IgG (6.67 nM) (upper panels) or ICSM-18 (6.67 nM) (lower panels). The cells were stained with an antibody to MAP2 to visualize dendrites. Boxed areas are enlarged below each image. Scale bar = 10 µm. Right, quantitation of dendritic degeneration, expressed as the length of beaded dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each experimental condition. Data represent mean ± S.E.M. \*\*\*p\<0.005. (**B**) Left, representative images showing dendrite morphology of cultured hippocampal neurons from Tga20 mice (left-hand panels) or *Prnp*^−/−^ mice (right-hand panels) after treatment for 48 hr with control scFv (anti-fluorescein, 200 nM) (upper panels) or ICSM-18 scFv (200 nM) (lower panels). The cells were stained with an antibody to MAP2 to visualize dendrites. Boxed areas are enlarged below each image. Scale bar = 10 µm. Right, quantitation of dendritic degeneration, expressed as the length of beaded dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each experimental condition. Data represent mean ± S.E.M. \*\*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.024](10.7554/eLife.23473.024)

Discussion {#s3}
==========

In this study, we have investigated two potentially interrelated functional activities of the PrP^C^ molecule: its ability to induce ionic currents, and its ability to cause degenerative changes in neurons. Both activities are associated with deletions spanning the central region of the protein (residues 105--125), as well as with binding of antibodies to overlapping epitopes on the outer surface of helix 1 in the structured, C-terminal domain of the protein. Both activities are dependent on the flexible, N-terminal domain of PrP^C^, and are blocked by deletion or mutation of this domain, or by binding of specific ligands to the N-terminal domain. When fused to an unrelated protein (EGFP), the N-terminal domain is sufficient by itself to induce current activity in the absence of the C-terminal domain. Taken together with evidence from heteronuclear NMR experiments, these results suggest a molecular model in which the N-terminal domain represents a toxic effector whose activity is regulated by the C-terminal domain, most likely by a Cu^2+^-promoted physical interaction between the two domains. We speculate that alterations of this intramolecular regulation may have both pathological and physiological consequences.

The N-terminal domain of PrP^C^ is necessary and sufficient for current activity {#s3-1}
--------------------------------------------------------------------------------

Our previous studies identified a nine amino-acid polybasic region at the N-terminus of PrP^C^ (residues 23--31) that is essential for several toxic activities, including the spontaneous current activity associated with the ΔCR PrP deletion mutant, the antibiotic hypersensitivity of cells expressing ΔCR PrP, and the neurodegenerative phenotype of transgenic mice expressing the deletion mutant Δ34--121 ([@bib43]; [@bib56]). In the present study, we have shown that reversal of positive charges within this region (three lysine residues and one arginine residue) abolishes ΔCR current activity, as does treatment with ligands (antibodies, Cu^2+^ ions, pentosan sulfate) that bind to this region or to other sites within the flexible N-terminal domain (residues 23--125). Strikingly, the isolated N-terminal domain fused to an unrelated protein (EGFP) has the ability to induce spontaneous ionic currents. The magnitude of these currents is quantitatively related to the length of the N-terminus incorporated (fusions ending at residues 31, 58, 90, and 109 produce progressively more current), and the activity of these constructs is entirely dependent on the presence of the 23--31 region. Taken together, these results suggest that the N-terminal domain of PrP^C^ acts as an autonomous effector of ionic current activity, and that basic amino acids at the extreme N-terminus are essential for this activity.

We suggest two possible models to explain how the N-terminal domain induces currents. One model is based on the fact that polybasic residues 23--31 resemble a 'protein transduction domain', originally described in the HIV Tat protein ([@bib52]). Such positively charged domains are capable of penetrating lipid bilayers and creating pores, by virtue of binding to and disrupting membrane phospholipids ([@bib16]). The N-terminal domain of PrP^C^ may thus function as a 'tethered' protein transduction domain capable of spontaneously and transiently penetrating the lipid bilayer to produce pores that allow passage of ions. Consistent with penetration of a positively charged protein domain into or across the cell membrane, we find that the ionic current activity associated with both ΔCR and PrP(N)-EGFP-GPI is apparent only at hyperpolarized holding potentials (\<−30 mV), similar to the resting potential of neurons (−60 to −70 mV). A second possibility is that the N-terminal domain interacts with other membrane proteins, for example endogenous ion channels or channel-modulating proteins, to induce current activity. Supporting this hypothesis is our observation that co-expression of wild-type PrP^C^ suppresses the ionic currents induced by ΔCR and PrP(N)-EGFP-GPI, a phenomenon that could be attributable to competition between the wild-type and mutant forms for a common membrane-associated target protein.

Antibodies to the C-terminal domain induce currents {#s3-2}
---------------------------------------------------

Three different antibodies (POM1, D18, ICSM-18) targeting the C-terminal domain all induce ionic current activity in cells expressing WT PrP^C^. Importantly, the properties of these currents are identical to those of the spontaneous currents associated with ΔCR PrP, in terms of their sporadic nature, their blockage by N-terminal ligands (PPS, antibodies), and their absolute dependence on the presence of the polybasic 23--31 region. Based on crystal structures, mutagenesis studies, and peptide arrays, the epitopes of these antibodies, while not identical, are largely overlapping and encompass the outer surface of helix 1, as well as parts of the β1-α1 loop and helix 3 in the case of POM1 ([@bib1]; [@bib12]; [@bib44]). Three different antibodies (POM3, D13 and ICSM-35) recognizing a basic region following the octapeptide repeats (residues 93--110) were ineffective at inducing currents, although a fourth one (6D11) had a weak effect at high concentrations. Two other antibodies targeting additional epitopes in the C-terminal domain had no effect. [Table 1](#tbl1){ref-type="table"} summarizes the effects of the antibodies on current activity.10.7554/eLife.23473.025Table 1.Anti-prion antibodies used in this study, and their ability to induce ionic currents and dendritic toxicity.**DOI:** [http://dx.doi.org/10.7554/eLife.23473.025](10.7554/eLife.23473.025)AntibodyEpitopeCurrentsDendritic toxicityD18 (holo and Fab)132--156 (α1)YesYesPOM1138-147/204,8,12 (α1/α3)YesYesICSM18 (holo and scFv)143--156 (α1)YesYes6D1193-109/97-100WeakWeakICSM3593--105NoNoD1395--105NoNoPOM4121-134/218-21 (β1/α3)NoNoPOM6140/145/174/177 (α1/ α2)NoNoPOM11\*51--90 (octarepeats)NoNo[^1]

Together, these findings suggest a novel intramolecular regulatory mechanism controlling the activity of PrP^C^ ([Figure 8A](#fig8){ref-type="fig"}). Published crystal structures of both POM1 ([@bib44]) and ICSM-18 ([@bib1]) bound to PrP^C^ indicate that these antibodies do not induce major structural alterations in the PrP^C^ globular domain compared to the unliganded state, arguing against antibody-induced allosteric changes as a toxic mechanism. Rather, our results suggest that antibodies bound to helix 1 disrupt a critical regulatory interaction between the N- and C-terminal domains, thereby liberating the N-terminal domain to produce toxic effects ([Figure 8B](#fig8){ref-type="fig"}). The fact both Fab and scFv forms of the relevant antibodies display current-inducing activity suggests that antibody ligands as small as 25--50 kDa are able to disrupt N-C interactions. We propose that a similar loss of regulation occurs when residues within the 95--125 region are deleted (as in ΔCR), or when an unrelated protein is substituted for the C-terminal domain (PrP(N)-EGFP-GPI) ([Figure 8C,D](#fig8){ref-type="fig"}). In this scenario, the toxic activity of the liberated N-terminal domain would be blocked by binding of ligands, including PPS, antibodies, or Cu^2+^ ions ([Figure 8E](#fig8){ref-type="fig"}).10.7554/eLife.23473.026Figure 8.Models for the neurotoxic effects of PrP.(**A**) The C-terminal domain of PrP^C^ negatively regulates the toxic effector function of the N-terminal domain. +++, basic residues within the 23--31 region at the extreme N-terminus, which are essential for the toxic action of PrP. (**B**) Binding of monoclonal antibodies to the C-terminal domain disrupts this regulatory interaction, releasing the N-terminal domain to produce toxic effects. (**C**) Deletion of the central region, as in ΔCR PrP, produces a similar loss of regulation, with toxic consequences. (**D**) When EGFP is substituted for the C-terminal domain of PrP^C^, regulation is also lost. (**E**) Binding of ligands (PPS, antibodies, Cu^2+^) to the N-terminal domain of ΔCR PrP blocks its ability to exert toxic effects. These ligands would have a similar, inhibitory effect on PrP(N)-EGFP-GPI (not shown).**DOI:** [http://dx.doi.org/10.7554/eLife.23473.026](10.7554/eLife.23473.026)

The model proposed in [Figure 8](#fig8){ref-type="fig"} is supported by biophysical evidence. NMR studies performed here as well as previously ([@bib13]; [@bib45]) demonstrate that the N-terminal domain docks onto the C-terminal domain, thereby regulating in cis the ability of the N-terminal domain to promote toxic effector functions under normal conditions. Of note, the docking site encompasses the POM1 epitope ([@bib13]). Thus, binding of antibodies to this region would be predicted to disrupt the N-C interaction, leading to toxic activity. We also show here that deletion of the central region (in ΔCR PrP) weakens Cu^2+^-induced N-C interaction, consistent with the hypothesis that the toxicity of the ΔCR mutant results from disrupted regulation of the N-terminal domain. Cu^2+^ ions are physiological ligands of PrP^C^ ([@bib27]), and changes in endogenous Cu^2+^ concentration are likely to modulate the strength of N-C interactions. Cu^2+^ binding to the octarepeats may also directly suppress the toxic activity of the N-terminal domain, as we have observed for the currents induced by ΔCR PrP and PrP(N)-EGFP-GPI.

C-terminally directed antibodies induce dendritic degeneration {#s3-3}
--------------------------------------------------------------

In addition to acutely inducing ionic currents, helix 1 antibodies (POM1, D18, ICSM18) cause major changes in dendritic morphology of cultured hippocampal neurons, in particular the appearance of blebs or varicosities, when applied for longer periods of time (48 hr) ([Table 1](#tbl1){ref-type="table"}). These antibody-induced dendritic changes are, like the currents induced by the same antibodies, entirely dependent on the N-terminal domain of PrP^C^, and are blocked by N-terminal ligands and deletions of residues 23--31.

The parallel characteristics of the ionic currents and the dendritic changes induced by C-terminal antibodies suggest a mechanistic connection between the two phenomena. One possibility is that chronic activation of PrP^C^-mediated currents leads directly or indirectly to dendritic degeneration. Consistent with this possibility, dendritic varicosities similar to those caused by anti-PrP antibodies are a characteristic feature of glutamate excitotoxicity ([@bib15]), and glutamate excitotoxicity has been implicated in the neuronal degeneration induced by ΔCR PrP ([@bib4]; [@bib9]). A second possibility is that current induction and dendritic degeneration are parallel events that represent two distinct outputs of antibody binding to PrP^C^. For example, the N-terminal domain of PrP^C^ may stimulate currents by interacting with the lipid bilayer, and dendritic changes by interacting with signal-transducing proteins embedded in the membrane.

Several other studies have reported toxic effects of anti-PrP antibodies, including several of the ones used here, although some of these results have been contradictory. It has been reported that antibodies D13 ([@bib33]; [@bib40]), POM1 ([@bib44]), and ICSM-18 ([@bib33]), but not D18 ([@bib40]), caused acute death (within 24--48 hr) of neurons when injected stereotaxically into the hippocampus or cerebellum. Using a similar protocol, however, [@bib21] found that D13 and ICSM-18 were non-toxic, as was ICSM-35. Finally, [@bib44] observed that chronic treatment (10--21 days) of cerebellar slices with several C-terminally directed antibodies, including POM1, caused neuronal death, and they concluded that this effect was dependent on the flexible N-terminal domain. The results presented here are consistent with this proposal.

It has been reported that anti-PrP antibodies trigger several toxic mechanisms in cerebellar slices, including generation of reactive oxygen species, calpain activation and stimulation of the PERK arm of the unfolded protein response ([@bib44]). Whether these pathways are operative in our system remains to be determined. Since we observe relatively acute changes in dendritic morphology without loss of neuronal viability, it is possible that the downstream toxic pathways engaged by antibody treatment in our system may be different.

Implications {#s3-4}
------------

The results presented here have several important implications. First, they add to concerns that have been raised regarding the use of anti-PrP antibodies as therapeutic tools for treatment of prion diseases ([@bib57]) and Alzheimer's disease ([@bib20]), given the potential side-effects of these reagents on neuronal viability at nanomolar concentrations ([@bib33]; [@bib40]; [@bib44]).

Second, our results also suggest a mechanism by which pathologic ligands that bind to PrP^C^ could produce neurotoxic effects by disrupting the normal regulatory cis-interaction between the N- and C-terminal domains, similar to the action of the antibodies described in this study. The Alzheimer's Aβ peptide, which binds to PrP^C^ and triggers functional and structural alterations in synaptic transmission ([@bib22]), is an example of such a ligand. PrP^Sc^, which also binds to PrP^C^ ([@bib41]), might act in a similar fashion, although the fact that mice expressing N-terminally truncated PrP^C^ remain susceptible to prion diseases ([@bib46]; [@bib50]) argues against this as the primary pathogenic mechanism in these disorders.

Finally, it is possible that the antibody-induced effects we have observed here are a reflection of a physiological activity of PrP^C^. If so, natural ligands, including proteins, small molecules or metal ions, may exist, whose binding to PrP^C^ regulates an effector activity of the N-terminal domain, similar to the way that we suppose anti-PrP antibodies operate. Copper ions are examples of natural ligands, binding of which to the octapeptide repeats promotes docking of the N- and C-terminal domains ([@bib13]; [@bib45]). Endogenous ligands for the globular domain may also exist, which either enhance or disrupt N-C interaction. Previous studies have implicated the N-terminal domain of PrP^C^ in several physiological activities of PrP^C^ ([@bib29]; [@bib30]; [@bib35]; [@bib39]; [@bib47]; [@bib54]), some of which may be regulated by interaction with the C-terminal domain.

Materials and methods {#s4}
=====================

Antibodies and other reagents {#s4-1}
-----------------------------

POM1, POM3, POM4, POM6 and POM11 antibodies ([@bib31]) were provided to J.T. by the University of Zürich, Institute of Neuropathology. Hybridomas producing the human-mouse chimeric monoclonal antibodies D13 and D18 ([@bib34]; [@bib58]) were provided by Anthony Williamson, Dennis Burton, and Bruce Chesebro. Antibodies were affinity-purified using protein A spin columns (Montage Antibody Purification Kit, EMD Millipore). Fab fragments of D18 were prepared using the Pierce Fab preparation kit from Thermo Scientific. The purity of all antibody preparations was verified by SDS-PAGE. The following antibodies were purchased from commercial sources: 100B3 (Wagening UR, Netherlands); 6D11 (BioLegend, cat \#808001); ICSM-18 and ICSM-35 (D-Gen Ltd.).

Pentosan polysulfate (average MW = 4500--5000) was purchased from Biopharm Australia Pty Ltd., and phosphatidylinositol-specific phospholipase C from Sigma (cat \#P5542).

Expression and purification scFv antibodies {#s4-2}
-------------------------------------------

The genes encoding the scFv form of ICSM18, constructed as described ([@bib12]), and anti-fluorescein 4-4-20 scFv (negative control; obtained from Anne S. Robinson) were subcloned into pHAGE-CMV-dsRed-UBC-GFP-W (Addgene plasmid \#24526) in place of dsRed by restriction digest cloning such that the final construct included an N-terminal Igκ light chain secretion signal and a C-terminal FLAG tag (DYKDDDDK) fused to the scFv, while maintaining the separate ORF expressing GFP as a reporter. Lentivirus was generated by co-transfection of 5 × 10^5^ HEK cells with 1.3 µg pHAGE expression vector, 1 µg psPax2, and 0.65 µg pMD2.G (Addgene plasmids \#12260 and \#12259) with TransIT-293 transfection regent (Mirus Bio LLC). After 72 hr, the supernatant was filtered with a 0.45-µm syringe-tip filter and used directly for transduction.

CHO-S cells adapted to serum-free suspension culture (kindly provided by Kelvin H. Lee) were grown in serum-free culture medium (Thermo Fisher Scientific, SH3054902) in vent-cap shake flasks in a humidified incubator at 37°C/5% CO2. Stable CHO cell lines were created by transducing 5 × 10^5^ CHO cells in 9 ml with 1 ml of HEK supernatant containing lentiviral particles in the presence 6 µg/ml polybrene (Sigma-Aldrich) for 2 days. Transduced cells were separated from non-transduced cells based on GFP reporter expression by fluorescence-activated cell sorting (FACS) using a BD FACSAria II FACS machine. Production of scFv was carried out by culturing the CHO lines for 7 days; initial cultures contained 5 × 10^5^ cells/ml. Supernatant was harvested by centrifugation and filtration with a 0.22-µm syringe-tip filter before purification by anti-FLAG-affinity chromatography (Sigma-Aldrich) and low-pH elution according to the manufacturer's protocol. Eluted scFv was concentrated and buffer-exchanged with a 10 kDa molecular weight cut-off centrifugal filter, assayed by silver stain to ensure purity \>90%, and quantified by Bradford assay. Purified scFv was stored in Tris-buffered saline at 4°C for short-term use, or −20°C for long-term storage.

Plasmids {#s4-3}
--------

pcDNA3.1(+)Hygro plasmids (Invitrogen) encoding WT, ΔCR, ΔCR/Δ51--90, or Δ23--31 PrP have been described previously ([@bib42], [@bib43]; [@bib49]). PrP(N)-EGFP-GPI constructs were created by fusing DNA sequences encoding residues 1--31, 1--58, 1--90, 1--109 or 32--109 of mouse PrP to residues 1--239 of EGFP, followed by a poly-glycine/serine linker (GGGGS)~4~ and then by residues 222--254 of mouse PrP in order to maintain GPI anchoring of the fusion protein. The ΔCR/E3D plasmid encodes ΔCR PrP with the following mutations: K23E, K24E, R25D and K27E.

Cells {#s4-4}
-----

N2a cells (Cat. \#: ATCC CCL-131, RRID: [CVCL_0470](https://scicrunch.org/resolver/CVCL_0470)) were maintained in DMEM supplemented with nonessential amino acids, 10% fetal bovine serum and penicillin/streptomycin. The N2a cell line we used in this study is mycoplasma free. Cells were transiently transfected using Lipofectamine 2000 with pEGFP-N1 (Clontech), along with empty pcDNA3.1(+)Hygro vector, or vector encoding WT or mutant PrPs. Cell-surface expression of all PrP constructs was confirmed by immunofluorescence staining.

Hippocampi from the newborn pups of the indicated genotypes were dissected and treated with 0.25% trypsin at 37°C for 12 min ([@bib36]). Cells were plated at a density of 65,000 cells/cm^2^ on poly-D-lysine-coated coverslips in DMEM medium with 10% F12 and 10% FBS.

Mice {#s4-5}
----

*Prnp*^−/−^ (Zurich I) mice ([@bib7]) on the C57BL6 background, and Tga20 mice ([@bib14]) have been described previously, and were obtained from EMMA (European Mouse Mutant Archive). Tg(PrPΔ23--31) mice ([@bib49]) and Tg(PrPΔ23--111) mice ([@bib55]) have been described previously, and were maintained on a *Prnp^-/-^* background. Wild-type C57BL6 mice were obtained from Charles River Laboratories.

Electrophysiological analysis {#s4-6}
-----------------------------

Recordings were made from N2a cells 24--48 hr after transfection. Transfected cells were recognized by green fluorescence resulting from co-transfection with pEGFP-N1. Hippocampal neurons were analyzed after 13--15 days in culture. Whole-cell patch clamp recordings were collected using standard techniques. Pipettes were pulled from borosilicate glass and polished to an open resistance of 2--5 megaohms. Experiments were conducted at room temperature with the following solutions: internal, 140 mM Cs-glucuronate, 5 mM CsCl, 4 mM MgATP, 1 mM Na~2~GTP, 10 mM EGTA, and 10 mM HEPES (pH 7.4 with CsOH); external, 150 mM NaCl, 4 mM KCl, 2 mM CaCl~2~, 2 mM MgCl~2~, 10 mM glucose, and 10 mM HEPES (pH 7.4 with NaOH). Current signals were collected from a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), digitized with a Digidata 1440 interface (Molecular Devices), and saved to disc for analysis with PClamp 10 software.

Localization of PrP^C^ on N2a cells {#s4-7}
-----------------------------------

Immunofluorescence staining of cell surface PrP^C^ on N2a cells was performed by incubating livings cells on ice with D18 antibody, fixing in 4% paraformaldehyde in PBS, and then labeling with Alexa Fluor 594 goat anti-human IgG (Molecular Probes, Eugene, OR). Images of N2a cells were acquired with a Zeiss LSM 710 confocal microscope.

Morphological analysis of hippocampal neurons {#s4-8}
---------------------------------------------

Neurons cultured for 14 days were fixed with 4% paraformaldehyde in PBS and permeabilized with 0.2% Triton100. Fixed cultures were then incubated with primary antibodies against microtubule-activated protein 2 (MAP2; polyclonal; 1:1000; Abcam), followed by fluorescent secondary antibody. Confocal microscopic analysis was performed on a Zeiss LSM 710 microscope using a 20X objective lens. Identical acquisition settings were applied to all samples of the experiment. Images were analyzed with the NIH Image J program.

Preparation of recombinant PrP for NMR {#s4-9}
--------------------------------------

Recombinant PrP constructs encoding wild-type mouse PrP(23-230) and mouse ΔCR PrP(Δ105--125) in the pJ414 vector (DNA 2.0) were expressed in *E. coli* (BL21 (DE3) Invitrogen) ([@bib13]). Mutations were introduced using PCR-based, site-directed mutagenesis with mutagenic primers (Invitrogen) and Phusion DNA Polymerase (Finnzymes). All constructs were confirmed by DNA sequencing.

Bacteria were grown in M9 minimal media supplemented with ^15^NH~4~Cl (1 g/L) for ^1^H-^15^N HSQC experiments or ^15^NH~4~Cl and ^13^C6-glucose (2.5 g/L) for ^1^H, ^13^C, ^15^N triple-resonance experiments (Cambridge Isotopes). Cells were grown at 37°C until reaching an optical density (OD) of 0.6, at which point expression was induced with 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG). PrP constructs were purified as previously described ([@bib45]). Briefly, proteins were extracted from inclusion bodies with 8 M guanidium chloride (GdnHCl) (pH 8) at room temperature and were purified by Ni^2+^-immobilized metal-ion chromatography (IMAC). Proteins were eluted from the IMAC column in 5 M GdnHCl (pH 4.5) and were brought to pH 8 with KOH and left at 4°C for 2 days to oxidize the native disulfide bond. Proteins were then desalted into 10 mM KOAc buffer (pH 4.5) and purified by reverse-phase HPLC on a C4 column. The purity and identity of all constructs were verified by analytical HPLC and mass spectrometry (ESI-MS). Disulfide oxidation was confirmed by reaction with N-ethylmaleimide and subsequent ESI-MS analysis.

Lyophilized protein samples were dissolved in degassed Milli-Q-purified H~2~O and allowed to fully solubilize prior to all experiments. Protein concentrations were determined from the absorbance at 280 nm in GdnHCl buffer using an extinction coefficient of 64,840 M^−1^ cm^−1^ calculated for mouse PrP(23-230) and 62,280 M^−1^cm^-1^ calculated for mouse ΔCR PrP(Δ105--125). For samples containing Cu^2+^, the metal ion was added from stock solutions of Cu(OAc)~2~ or CuCl~2~ in H~2~O in which the Cu^2+^ concentrations were accurately determined by EPR integration ([@bib53]). Samples for NMR contained 200--400 µM PrP in 10 mM MES buffer (pH 6.1) with 10% D~2~O.

^1^H-^15^N HSQC NMR {#s4-10}
-------------------

NMR experiments were conducted on a Varian INOVA 600 MHz spectrometer equipped with a ^1^H, ^13^C, ^15^N triple-resonance cryoprobe. Resonance assignments were first obtained using standard triple-resonance experiments with a 400 µM samples of uniformly ^13^C,^15^N-labeled mouse PrP(23-230) sample at 25°C. Experiments included HNCO, HN(CA)CO, HNCACB, CBCA(CO)NH, and CC(CO)NH. The assignments were then transferred to the ^1^H-^15^N HSQC spectrum at 300 µM and 37°C by following the cross-peaks through concentration and temperature titrations. Resonances were confirmed, and additional resonances were assigned by recording three-dimensional HNCACB and ^15^N-NOESY-HSQC spectra at 300 µM and 37°C. Finally, resonance assignments were transferred to the ^1^H,^15^N HSQC spectrum of MoPrP (H95Y/H110Y) at 300 µM and 37°C by visual inspection. All NMR spectra were processed with NMRPipe and NMRDraw ([@bib11]), and analyzed using Sparky NMR Analysis and CcpNmr Analysis ([@bib51]).

^1^H,^15^N HSQC spectra were recorded for MoPrP (H95Y/H110Y) and MoPrP(Δ105--125)H95Y constructs (300 µM) at 37°C both in the absence of metal ions and in the presence of 300 µM CuCl~2~, and the HSQC peak intensities were determined using Sparky NMR Analysis and CcpNmr Analysis. Intensity ratios were analyzed using Kaleidagraph (Synergy Software) and residues with intensity reductions greater the one standard deviation of the mean were considered significantly perturbed.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The N-terminus of the Prion Protein Is a Toxic Effector Regulated by the C-terminus\" for consideration by *eLife*. Your article has been favorably evaluated by Rob Krumlauf (Senior Editor) and four reviewers, one of whom is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: Surachai Supattapone (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors present data from multiple complementary approaches, and build upon prior results, to elucidate the role of the N-terminal domain of PrP in mediating ionic membrane currents and neuronal degeneration. The reviewers are enthusiastic about insights into a potential mechanism for the toxicity of certain anti-PrP antibodies, which may help to resolve the current controversy about using these antibodies in human immunotherapy trials. The model may help explain the toxicity of Abeta oligomers, which bind to PrPC, although this isn\'t directly tested. The reviewers have elaborated several questions and concerns that must be addressed before this manuscript can be considered for publication.

Essential revisions:

1\) The reviewers point out two apparent inconsistencies that need resolution: First, the failure of the 1-31-EGFP and 1-59-EGFP constructs to induce currents is puzzling since the deltaCR/delta51-90 mutant is very active in this regard and nearly identical to these EGFP constructs in terms of the N-terminal domain. Second, the lack of antibody-induced currents or toxicity in the delta23-31 cells and transgenic mouse neurons is surprising since one would expect that wild-type levels of PrP are present.

2\) The relevance of the current findings to disease is incompletely explored. Whereas the connection between the toxicity of the POM1 and d13 antibodies with the ionic current mechanism is novel and interesting, the authors also speculate that the N-terminus of PrPC may be the mediator of PrPSc- and Abeta-induced neurodegeneration. This can be addressed by emphasizing that the mechanism explored relates to antibody-induced current only. Alternatively, to support the relationship to PrPSc- and Abeta-induced neurodegeneration, the reviewers have requested further elucidation of this connection and suggested additional experiments in this regard. Specifically, one reviewer expressed skepticism that the N-terminus of PrPC is required for the PrPSc-induced neurodegeneration since transgenic mice expressing N-terminally truncated PrPC develop spongiform degeneration following prion inoculation (J Virol. 2001 Feb;75(3):1408-13). On the other hand, perhaps the N-terminus of PrPC is required for Abeta-mediated toxicity, and we encourage the authors to test this directly (e.g. does application of Abeta oligomer cause the current?) Also, do recombinant PrP oligomers or fibrils induce currents?

*Reviewer \#1:*

The PrPc protein harbors an intrinsically disordered segment between aa23-125. It was previously noted that expression in mice of a mutant form of PrPc with internal deletions of aa102-125 result in degeneration in the absence of PrP amyloid assembly and, furthermore, that this toxicity is suppressed in a dose-dependent manner by OE of wild type PrPc. In parallel it was noted that expression of internal deletion mutants of PrPc in cell lines induce spontaneous ionic currents that are also suppressed by OE of wild type PrPc, although a cause-and-effect relationship between ionic current induction and degeneration remains to be established. The current study focuses on the role of the N-terminus of PrPc in mediating the toxicity.

Within the N-terminus of PrPc, prior studies suggested that a charged region (aa23-31) is essential for current induction by expressing PrPc-delta105-125 in cells and also degeneration in mice expressing PrPc-delta32-134. Prior studies also showed that treatment of cells with pentosan polysulfate (PPS, which purportedly binds to the N-terminus of PrPc) also abolished current induction. Here the investigators show that treatment with anti-PrPC antibodies 100B3 (epitope aa24-28) and POM11 (epitope aa51-90) both reduce current induction in N2a cells expressing mutant deltaCR PrPc. Deletion of the epitope for POM11, a region of octapeptide repeats, eliminates the effect of POM11 treatment. Further investigating the octapeptide repeats they use show that addition of Cu++, which purportedly binds the octapeptide repeats reduces current induction in N2a cells expressing mutant deltaCR PrPc, similar to antibody binding. Further confirming the importance of the positively charged region, a mutant (E3D, in which 3 charges are reversed) also abolished current-inducing activity. Interestingly, it is shown that the N-terminal domain itself (aa1-109), in the absence of the C-terminal domain, is sufficient to induce spontaneous currents. This activity reduces with smaller fragments. These currents are inhibited by ligands, including PPS, Cu++, and antibodies 100B3 and POM11. NMR-based interrogation suggests that aa102-125 deletion, which correlates with current induction, reduces interaction between the C-terminus and N-terminus of PrPc. Antibodies targeting the C-terminal folded domain also induced spontaneous currents, and expression of PrPc-delta23-31 were resistant to current induction. One antibody (D18) failed to induce currents in cells pre-treated with PIPLC to cleave PrPc, or in cells with PrPc knockout.

The proposal that a disinhibited native function of PrPc mediates the toxicity of PrPsc (and perhaps A-β), and that the mechanism relates to disturbance of association between the C-terminal and N-terminal domains of PrPc is certainly intriguing. As an outsider to the prion field, I find this line of investigation fascinating. With respect to the current work, I find compelling the evidence that the C-terminus of PrPc suppresses an activity of the N-terminus that underlies the induction of a spontaneous ionic current. I have several experimental questions, but the two more important issues to me are:

1\) what is the disease relevance of the spontaneous currents examined here? and 2) to what extent does this work provide a conceptual advance or mechanistic insight beyond what was previously known? First, with respect to the spontaneous currents elicited by expression of mutant PrPc (PrPc-delta105-125), as far as I can tell there is no established cause-and-effect relationship with degeneration, merely a correlation between induction of these currents in cell culture and degeneration in cells or in mice. Even if it is clear that spontaneous currents associated with forms of PrPc with internal deletions can drive toxicity, is this toxic gain of function relevant and essential to degeneration driven by PrPsc (and A-β)? Second, it appears that prior work has already established that PrPc deletion mutants induce spontaneous currents that are mitigated by N-terminal binding ligands, that the N-terminus interacts with the C-terminus, and that similar currents can be induced by antibodies targeting certain C-terminal epitopes. Just how much of a mechanistic advance does the current paper represent?

*Reviewer \#2:*

This important study by Wu and colleagues focuses on understanding the mechanism of neurotoxicity induced by PrPC. These new results shed light on how PrP can trigger ionic currents and neuronal degeneration, and also provide hints into the physiologic function of PrPC. Residues 23-26 in the N-terminus of PrP were previously identified as key to inducing spontaneous ionic currents in cells with deletions in the central region of PrP (105-125). Here, in a carefully controlled series of experiments, additional ligands specific for the N-terminus abolished spontaneous ionic currents, as did mutating the suspected N-terminal lysine residues. The C-terminus of PrP was not required for the induction of ionic currents. The experiments are well-designed and logical, and for the most part, clearly described. Inclusion of relevant negative data would be informative (noted below). Overall this work is a highly significant contribution toward understanding prion protein pathophysiology, and may have implications for AD since amyloid-β oligomers may bind PrPC and lead to neuronal toxicity.

Suggestions for improving the manuscript clarity are noted below.

1\) Whether ionic currents are induced during prion disease is unclear. Did the authors test recPrP oligomers or fibrils for induction of currents?

2\) Three antibodies targeting C-terminal epitopes in PrP were found to induce spontaneous currents, but it is unclear how many antibodies were tested. Were antibodies to other C-terminal epitopes tested (i.e. helix 3)? These would provide additional support for helix 1 specificity.

3\) Further description of the NMR methods and analysis in the Results is necessary for clarity, i.e., what residues in the C-terminus were impacted by copper binding to the OR? This seems to be the key point of these results, yet the interaction patch is not described beyond helices 2 and 3 in the C-terminus. From the figure, it appears that there is no longer an interaction with helix 3. Also a brief explanation of the NMR spectra would be helpful. Also the reference to the methods used from the Evans et al. study is unclear, was there a key part of the methods employed?

4\) The currents in untransfected N2a were reported as smaller, but the figure shows fewer (% of time). How much smaller were the currents in the untransfected cells?

5\) Subsection "Antibodies against the C-terminal domain and hinge region of PrP^C^ induce ionic currents", last paragraph -- Were anti-PrP antibodies tested in WT hippocampal neurons tested in addition to the tga20 neurons? It would be important to know whether overexpression was required to observe currents or the dendritic degeneration in neurons. Please clarify.

6\) Adriano Aguzzi and colleagues have published several high profile papers on prion-induced toxicity, also describing the N-terminus as an effector regulated by the C-terminal domain. It would be important to discuss how the results here correspond to these findings from the field.

7\) In previous reports, the PERK arm of the UPR was activated following exposure to anti-PrP C-terminal antibodies (Hermann et al., 2015 PLoS Pathogens). Did the authors test whether the PERK pathway was activated in the hippocampal neurons? Or whether calpain activation occurred (as observed in the Sonati et al. study, Nature 2013)?

8\) The beaded appearance of the dendrites in [Figure 5](#fig5){ref-type="fig"} is difficult to appreciate in these small images.

9\) Typo in [Figure 2C](#fig2){ref-type="fig"} -- Figure shows results from a deletion of 32-109, but legend states deletion of 23-109.

*Reviewer \#3:*

I think this is an outstanding manuscript. The authors use a multidisciplinary approach (electrophysiology, NMR, antibodies, mutagenesis, dendritic spine analysis) with appropriate controls to make an extraordinarily compelling case that the N-terminus of PrP mediates toxicity through inducing an ionic current in cells. The methods, data, rigor, and writing are all top-notch.

The work is very significant because it provides a mechanism for the toxicity of certain anti-PrP antibodies, which may help to resolve the current controversy about using these antibodies in human immunotherapy trials. The model may help explain the toxicity of Abeta oligomers, which bind to PrPC, although this isn\'t directly tested.

*Reviewer \#4:*

This manuscript examines the role of the N-terminal domain of the prion protein in mediating ionic membrane currents and neuronal degeneration. Previous result showed that the currents induced by the deltaCR PrP variant (missing residues 105-125) depend on a cluster of positive charges near the very N-terminus of the protein (residues 23-31), that a ligand to the N-terminus of the protein (PPS) eliminates the currents. They now show that two N-terminal epitope antibodies (100B3 and POM11) also reduce these currents, as does copper-2 binding, and as does mutation of 4 positive charges in the positive charge cluster to negative charges (E3D mutant).

A construct of the N-terminal domain fused to EGFP also elicits ionic currents, but N-terminally and C-terminally truncated versions induced less currents. Notably, here it is unclear why 1-31-EGFP and 1-58-EGFP were not active, since the deltaCR/delta51-90 mutant is very active and nearly identical to these EGFP constructs in terms of the N-terminal domain?

NMR then shows that the N-to-C-terminal contacts already demonstrated by Millhauser et al. in a previous publication are reduced for the deltaCR mutant. Notably, the data for the WT (panels A1 in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and panels A1, B1 and C1 in [Figure 3](#fig3){ref-type="fig"}) appear essentially identical to those previously published, raising the question of whether their inclusion is justified here, and at a minimum a reference must be included in the figure legend.

Antibodies to the folded C-terminal domain of PrP (POM1, D18 and ICSM-18), previously shown to be toxic, also induced currents that were suppressed by PPS and the POM11 antibody in cells expression WT PrP, but less current was induced for cells expressing PrP missing residues 23-31. The effects are eliminated by cleaving PrP from the membrane, and are observed in WT cells, including hippocampal neurons, but not in PrP KO cells. D18 and POM1 also caused changes in dendritic morphology. Interestingly, in N2A cells expressing delat23-31 or neurons from transgenic mice expressing PrP missing residues 23-31 or 23-111, no effect (currents or toxicity) was observed. However, would the WT protein in these cells/TG mice not be expected to be susceptible to the antibodies and to cause currents/toxicity/degeneration?

The authors conclude that the N-terminal domain of PrP is responsible for the ionic currents they observe, and propose either a TAT peptide like mechanism or via protein-protein interactions. The propose that these currents, which are induced by antibodies to the C-terminal folded domain, may be responsible for the toxicity of such antibodies, as well as the toxicity of PrpSC, which is also reported to bind to the C-terminal domain of PrpC.

This is an interesting paper, which attempts to tie together a variety of previous observations from these groups and others, namely that antibodies to PrP can be toxic, that the flexible N-terminus of the protein mediates toxicity as well as ionic currents, and that intra-molecular interactions between the N- and C-terminus may regulate the activity/toxicity of the N-terminus. However, much of this model has already been presented in the various prior studies, including previous NMR work and previous work on the deltaCR construct and on the 23-31 deletion. The work is logical extension of the prior studies, but falls out largely as might be expected. That said, there are some troubling discrepancies, including the failure of the 1-31-EGFP and 1-59-EGFP constructs to induce currents, the lack of antibody-induced currents/ toxicity in the delta23-31 cells and transgenic mouse neurons, and the lack of any data supporting a specific mechanism linking the ionic currents to cell toxicity.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"The N-terminus of the Prion Protein Is a Toxic Effector Regulated by the C-terminus\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Huda Zoghbi (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

Please revise the text of the manuscript to provide possible explanations for unanticipated results, as described by Reviewer \#1.

*Reviewer \#1:*

The authors have posited explanations for two of the deficits noted in my review of the manuscript, namely 1) that residues 91-104 may contribute to current induction in deltaCR/delta51-90 and are absent in 1-31-EGFP and 1-58-EGFP, or possibly that EGFP does not position 1-31 or 1-58 NTD sequences at the proper distance from the membrane; and 2) that no antibody-induced currents are observed in N2A cells transfected with delta23-31 PrP because this construct may compete for antibody binding or suppress endogenous PrP expression. These are valid potential explanations (though of course they could actually be tested!), but they do not make their way in any shape or form into the revised text. The authors should explicitly discuss these issues in the manuscript. Otherwise, despite the public review forum, these points will likely escape the notice of most readers.

*Reviewer \#2:*

The authors have satisfactorily addressed the concerns I had with the initial manuscript. The questions I had have now been clarified. This paper is an important contribution to understanding the mechanisms of PrP-mediated neurotoxicity.

*Reviewer \#3:*

I am satisfied with the authors\' response to my comments.

10.7554/eLife.23473.028

Author response

*Essential revisions:*

*1) The reviewers point out two apparent inconsistencies that need resolution: First, the failure of the 1-31-EGFP and 1-59-EGFP constructs to induce currents is puzzling since the deltaCR/delta51-90 mutant is very active in this regard and nearly identical to these EGFP constructs in terms of the N-terminal domain.*

There are at least two possible reasons why ΔCR/Δ51-90 PrP ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) was more effective at inducing currents than 1-31-EGFP or 1-59-EGFP ([Figure 2](#fig2){ref-type="fig"}). First, the ΔCR/Δ51-90 PrP construct contains additional sequences that are not present in the 1-31-EGFP or 1-59-EGFP constructs. In particular, ΔCR/Δ51-90 PrP contains residues 91-104, which are absent in 1-31-EGFP and 1-59-EGFP. These additional residues may enhance production of spontaneous currents, consistent with the general observation that PrP-EGFP chimeras incorporating longer stretches of the PrP N-terminus produced more currents ([Figure 2C](#fig2){ref-type="fig"}). A second possible explanation is that the EGFP portion of the chimeric constructs may position the PrP N-terminus at a different distance from the membrane, or in a different orientation, than the natural PrP^C^ C-terminus, and this may diminish the ability of the N-terminus to interact with the membrane to produce currents. It was necessary to substitute the C-terminal domain of PrP with EGFP in order to facilitate delivery of the proteins to the cell surface.

*Second, the lack of antibody-induced currents or toxicity in the delta23-31 cells and transgenic mouse neurons is surprising since one would expect that wild-type levels of PrP are present.*

In [Figure 6](#fig6){ref-type="fig"}, the Δ23-31 and Δ23-111 PrP transgenic mice used to derive the neurons were maintained on a PrP knockout background, so there is no wild-type PrP^C^ in those neurons. This has now been clarified in the legend. The Material and Methods section in the original manuscript incorrectly stated that these mice were maintained on a C57BL6 background; this has now been corrected.

In N2a cells expressing Δ23-31 PrP, one would expect a significant reduction in antibody-induced currents compared to cells over-expressing WT PrP (as was, in fact, observed in [Figure 4D](#fig4){ref-type="fig"}), since the endogenous level of WT PrP in N2a cells is low, and we have shown that untransfected cells display reduced currents after antibody treatment ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). The fact that the Δ23-31-expressing cells do not display even low levels of current due to endogenous PrP^C^ may be due to some suppression of endogenous PrP expression, or perhaps competition by the deleted protein for binding of the antibodies.

*2) The relevance of the current findings to disease is incompletely explored. Whereas the connection between the toxicity of the POM1 and d13 antibodies with the ionic current mechanism is novel and interesting, the authors also speculate that the N-terminus of PrPC may be the mediator of PrPSc- and Abeta-induced neurodegeneration. This can be addressed by emphasizing that the mechanism explored relates to antibody-induced current only. Alternatively, to support the relationship to PrPSc- and Abeta-induced neurodegeneration, the reviewers have requested further elucidation of this connection and suggested additional experiments in this regard. Specifically, one reviewer expressed skepticism that the N-terminus of PrPC is required for the PrPSc-induced neurodegeneration since transgenic mice expressing N-terminally truncated PrPC develop spongiform degeneration following prion inoculation (J Virol. 2001 Feb;75(3):1408-13). On the other hand, perhaps the N-terminus of PrPC is required for Abeta-mediated toxicity, and we encourage the authors to test this directly (e.g. does application of Abeta oligomer cause the current?) Also, do recombinant PrP oligomers or fibrils induce currents?*

We acknowledge that the proposed role of the PrP^C^ N-terminus in PrP^Sc^ and Aβ toxicity is speculative, and is not directly addressed by any of the experiments reported in the paper. We are currently performing experiments to test this hypothesis, but we feel that the results are properly the subject of another paper. It would seem perverse to omit completely any reference to the possible implications of our results for prion pathogenesis, particularly since this connection has already been proposed in two publications from the Aguzzi laboratory (Sonati et al., 2013; Herrmann et al., 2015). However, in line with the suggestion of the reviewers, we have revised the text of the Abstract, Introduction, and Discussion sections to downplay the connection to PrP^Sc^ and Aβ toxicity, and to emphasize the relevance of our findings to the use of anti-PrP antibodies in a clinical setting.

With regard to the role of the N-terminus in PrP^Sc^ toxicity, the reviewers rightly point out that mice expressing N-terminally truncated PrP^C^ are susceptible to prion disease (although with a protracted incubation time), as shown in the 2001 J. Virology publication, as well as in our own work (Turnbaugh et al., J. Neurosci. 32:8817-- 8830, 2012). We have now cited these papers in the Discussion section, in order to qualify our suggestion about the role of the N-terminus in PrP^Sc^ toxicity. However, we wish to point out that the results of these two studies do not definitively rule out a role for the N-terminal domain in PrP^Sc^ toxicity. Multiple pathogenic mechanisms likely contribute to neurodegeneration at different times during the course of chronic disorders like prion diseases, and eliminating one of these mechanisms (such as toxicity mediated by the PrP^C^ N-terminus) would still allow other mechanisms to remain operative and produce disease. Thus, a more accurate interpretation of the cited experiments is that the PrP^C^ N-terminal domain is not required for prion-induced neurodegeneration, but this domain could nevertheless still play a contributing role.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*Please revise the text of the manuscript to provide possible explanations for unanticipated results, as described by Reviewer \#1.*

*Reviewer \#1:*

*The authors have posited explanations for two of the deficits noted in my review of the manuscript, namely 1) that residues 91-104 may contribute to current induction in deltaCR/delta51-90 and are absent in 1-31-EGFP and 1-58-EGFP, or possibly that EGFP does not position 1-31 or 1-58 NTD sequences at the proper distance from the membrane; and 2) that no antibody-induced currents are observed in N2A cells transfected with delta23-31 PrP because this construct may compete for antibody binding or suppress endogenous PrP expression. These are valid potential explanations (though of course they could actually be tested!), but they do not make their way in any shape or form into the revised text. The authors should explicitly discuss these issues in the manuscript. Otherwise, despite the public review forum, these points will likely escape the notice of most readers.*

We have now prepared a second revised version in which we have incorporated into the Results section answers to the two questions raised by reviewer \#1. We hope that the manuscript will now be acceptable for publication.

[^1]: \*Blocks currents induced by D18 and POM1.
